Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (460)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003907 | Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver | completed | Phase 2 | 50 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02795429 | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | completed | Phase 1 / Phase 2 | 89 | Novartis PharmaceuticalsINDUSTRY | 8 | Jul 3, 2023 | clinicaltrials |
| NCT01897610 | Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC | completed | Phase 2 | 40 | GC Cell CorporationINDUSTRY | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02856815 | Safety and Efficacy of "Immuncell-LC" in TACE Therapy | completed | Phase 2 | 76 | GC Cell CorporationINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02513199 | Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 32 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02520141 | Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery | completed | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00813293 | Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer | completed | Phase 2 | 20 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT05213221 | Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients(CISLD-12) | completed | Phase 2 | 39 | Zhejiang UniversityOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT04044313 | HAIC Plus Lenvatinib and Toripalimab for Advanced HCC | completed | Phase 2 | 36 | Shi MingOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03841201 | Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | completed | Phase 2 | 50 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT03586973 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 34 | TakedaINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT02821754 | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 | clinicaltrials |
| NCT04124991 | Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC(SOLID) | completed | Phase 1 / Phase 2 | 24 | Seoul National University HospitalOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT01192971 | A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma(HCC) | completed | Phase 2 | 121 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT04194801 | A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 26 | CStone PharmaceuticalsINDUSTRY | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05471674 | Neoadjuvant Anti-PD1 in HCC | completed | Phase 2 | 20 | Dr Tan-to CHEUNGOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03648073 | [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 12 | University of Alabama at BirminghamOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT01642186 | Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) | completed | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT02794805 | Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis | completed | Phase 2 | 74 | Meridian Bioscience, Inc.INDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT04310709 | Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma(RENOBATE) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT00956930 | Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery | completed | Phase 2 | 45 | Northwestern UniversityOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT03379844 | HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients | completed | Phase 2 | 30 | UMC UtrechtOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01180959 | Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy | completed | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 78 | Can-Fite BioPharmaINDUSTRY | 5 | Oct 4, 2022 | clinicaltrials |
| NCT02024087 | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 21 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05517239 | Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment(PEACH) | completed | Phase 2 | 32 | Yonsei UniversityOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT01988493 | Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 117 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Aug 24, 2022 | clinicaltrials |
| NCT02115373 | c-Met Second-Line Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 66 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
| NCT02141906 | A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin | completed | Phase 2 | 20 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05502458 | Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor | completed | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT03163992 | Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib | completed | Phase 2 | 60 | Samsung Medical CenterOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT00247728 | PI-88 in Hepatocellular Carcinoma After Hepatectomy | completed | Phase 2 | 172 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 23, 2022 | clinicaltrials |
| NCT01261247 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 41 | Mayo ClinicOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT00790218 | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 19 | Can-Fite BioPharmaINDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT00867321 | Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 1 / Phase 2 | 24 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01164202 | Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer(SATURNE) | completed | Phase 2 / Phase 3 | 78 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT02178358 | A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 132 | Eli Lilly and CompanyINDUSTRY | 5 | Feb 25, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02392637 | Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT01900002 | Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT00374660 | Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 63 | Eisai Inc.INDUSTRY | 1 | Dec 8, 2021 | clinicaltrials |
| NCT03111732 | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2021 | clinicaltrials |
| NCT00844883 | Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma | completed | Phase 2 | 50 | Yale UniversityOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT02973516 | Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis | completed | Phase 2 | 41 | GuerbetINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03109886 | Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 31 | Tiziana Life Sciences LTDINDUSTRY | 3 | Oct 12, 2021 | clinicaltrials |
| NCT00914355 | Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2) | completed | Phase 2 | 92 | University Health Network, TorontoOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT00335829 | Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 26 | Yale UniversityOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02089763 | Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer | completed | Phase 2 | 27 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Aug 9, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 5, 2023source: clinicaltrials